Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julie Doostzadeh

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Toxicological Sciences : an Official Journal of the Society of Toxicology|October 18, 2006
Chemical genomic profiling for identifying intracellular targets of toxicants producing Parkinson's diseaseJulie Doostzadeh, Ronald W Davis, Guri N Giaever, et al.
Coronary Artery Disease|December 3, 2009
Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stentJulie Doostzadeh, Lee N Clark, Susan Bezenek, et al.
European Heart Journal|February 2, 2010
Randomized comparison of everolimus- and paclitaxel-eluting stents: pooled analysis of the 2-year clinical follow-up from the SPIRIT II and III trialsYoshinobu Onuma, Patrick W Serruys, Neville Kukreja, et al.
Plos One|July 17, 2008
High throughput automated allele frequency estimation by pyrosequencingJulie Doostzadeh, Shadi Shokralla, Farnaz Absalan, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|October 31, 2009
Clinical and angiographic outcomes with an everolimus-eluting stent in large coronary arteries: the SPIRIT III 4.0 mm registryPaul C Gordon, Robert J Applegate, James B Hermiller, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|May 28, 2010
Evaluation of the effects of everolimus-eluting and paclitaxel-eluting stents on target lesions with jailed side branches: 2-year results from the SPIRIT III randomized trialRobert Applegate, James Hermiller, Jerome Williams, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|October 2, 2010
Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trialRobert J Applegate, James J Hermiller, Mark Sanz, et al.
American Heart Journal|September 29, 2009
SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery diseaseEugenia Nikolsky, Alexandra J Lansky, Krishnankutty Sudhir, et al.
The American Journal of Cardiology|January 21, 2011
Long-term (three-year) safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents (from the SPIRIT III Trial)Robert J Applegate, Manejeh Yaqub, James B Hermiller, et al.
The New England Journal of Medicine|May 7, 2010
Everolimus-eluting versus paclitaxel-eluting stents in coronary artery diseaseGregg W Stone, Ali Rizvi, William Newman, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Toxicological Sciences : an Official Journal of the Society of Toxicology|October 18, 2006
Chemical genomic profiling for identifying intracellular targets of toxicants producing Parkinson's diseaseJulie Doostzadeh, Ronald W Davis, Guri N Giaever, et al.
Coronary Artery Disease|December 3, 2009
Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stentJulie Doostzadeh, Lee N Clark, Susan Bezenek, et al.
European Heart Journal|February 2, 2010
Randomized comparison of everolimus- and paclitaxel-eluting stents: pooled analysis of the 2-year clinical follow-up from the SPIRIT II and III trialsYoshinobu Onuma, Patrick W Serruys, Neville Kukreja, et al.
Plos One|July 17, 2008
High throughput automated allele frequency estimation by pyrosequencingJulie Doostzadeh, Shadi Shokralla, Farnaz Absalan, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|October 31, 2009
Clinical and angiographic outcomes with an everolimus-eluting stent in large coronary arteries: the SPIRIT III 4.0 mm registryPaul C Gordon, Robert J Applegate, James B Hermiller, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|May 28, 2010
Evaluation of the effects of everolimus-eluting and paclitaxel-eluting stents on target lesions with jailed side branches: 2-year results from the SPIRIT III randomized trialRobert Applegate, James Hermiller, Jerome Williams, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|October 2, 2010
Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trialRobert J Applegate, James J Hermiller, Mark Sanz, et al.
American Heart Journal|September 29, 2009
SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery diseaseEugenia Nikolsky, Alexandra J Lansky, Krishnankutty Sudhir, et al.
The American Journal of Cardiology|January 21, 2011
Long-term (three-year) safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents (from the SPIRIT III Trial)Robert J Applegate, Manejeh Yaqub, James B Hermiller, et al.
The New England Journal of Medicine|May 7, 2010
Everolimus-eluting versus paclitaxel-eluting stents in coronary artery diseaseGregg W Stone, Ali Rizvi, William Newman, et al.
Pageof 2